Radik S. Faskhutdinov
Research Subjects
Research Interests
Radik S. Faskhutdinov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Vladimirovna Vinokurova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Aleksej N. Katargin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Ekaterina A. Mustafina
Blokhin National Medical Research Center of Oncology
3 shared publications - Kirill I. Zhordania
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Larisa S. Pavlova
Blokhin National Medical Research Center of Oncology
3 shared publications - Maria Dmitrievna Fedorova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications
Latest Publications
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 195-210
Expression profile of cellular microRNAs and their potential role in cervical cancer
Background. Cervical cancer (CC) is the fourth leading cause of cancer-related morbidity and mortality among women. Despite the established etiologic factor of cervical cancer, especially high-risk human papillomavirus (HPV, human papillomavirus) and available vaccine prophylaxis, the issue persists both in understanding the mechanism of HPV-associated carcinogenesis and in developing new approaches for diagnosis and treatment of cervical cancer. Epigenetic regulation of gene expression by means of microRNAs plays an important role in the pathogenesis of cervical cancer. Therefore, the search for new differentially expressed microRNAs in order to reveal new mechanisms of HPV-associated transformation of tumor cells is of high priority. AIM: To explore microRNAs with differentiated expression in the cervical cancer tissue and to assess the functional potential of their detection in silico. MATERIALS AND METHODS: The spectrum of microRNAs characterizing by modified expression in the tumor tissue of HPV16-positive squamous cell carcinomas of the cervix was determined using NGS sequencing (Next Generation Sequencing) of tumor tissue and of apparently unchanged adjacent epithelium obtained with the use of microdissection. Potential target genes of the investigated microRNAs were identified using MirTargetLink, Tarbase v9.0, and LinkedOmics services. Gene Set Enrichment Analysis was performed using Metascape. The relations between the level of microRNA expression and clinical SCC features (according to TCGA data, CESC sample) were searched using USCS Xena service. RESULTS: NGS-sequencing of paired HPV16-positive specimens of tumor tissue and normal cervical tissue resulted in the identification of 42 differentially expressed microRNAs. Specifically, the levels of 22 microRNAs in the tumor tissue were higher than in the apparently normal adjacent epithelium, while 20 microRNAs demonstrated lower levels in the tumor specimens. Analysis of the potential targets of significant microRNAs revealed multiple functional gene categories, potentially involved in carcinogenesis as well as an association with clinical features. We showed that increased expression levels of microRNA-20b in the tumor tissue correlated with the risk of distant metastases, whereas the lower levels of microRNA-218-1 and microRNA -218-2 were associated with unfavorable prognosis of disease. With regard to microRNA-363, -615, and -769, their increase in cervical cancer was described for the first time, and the potential targets and signaling pathways associated with THEIR EXPRESSION LEVELS WERE IDENTIFIED. CONCLUSION: The search for differentially expressed microRNAs in cervical cancer has revealed a spectrum of microRNAs with potentially important role in the process of malignant transformation and persistence of tumor phenotype. In addition to microRNAs demonstrating functional characteristics described in the world literature, we found microRNAs that play an unknown role in cervical cancer. In this relation, the potentially relevant targets were identified that could be helpful in understanding the mechanisms of carcinogenesis. The data obtained may form the basis for the development of new approaches to the diagnosis and therapy of SCC.
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 195-210
Expression profile of cellular microRNAs and their potential role in cervical cancer
Background. Cervical cancer (CC) is the fourth leading cause of cancer-related morbidity and mortality among women. Despite the established etiologic factor of cervical cancer, especially high-risk human papillomavirus (HPV, human papillomavirus) and available vaccine prophylaxis, the issue persists both in understanding the mechanism of HPV-associated carcinogenesis and in developing new approaches for diagnosis and treatment of cervical cancer. Epigenetic regulation of gene expression by means of microRNAs plays an important role in the pathogenesis of cervical cancer. Therefore, the search for new differentially expressed microRNAs in order to reveal new mechanisms of HPV-associated transformation of tumor cells is of high priority. AIM: To explore microRNAs with differentiated expression in the cervical cancer tissue and to assess the functional potential of their detection in silico. MATERIALS AND METHODS: The spectrum of microRNAs characterizing by modified expression in the tumor tissue of HPV16-positive squamous cell carcinomas of the cervix was determined using NGS sequencing (Next Generation Sequencing) of tumor tissue and of apparently unchanged adjacent epithelium obtained with the use of microdissection. Potential target genes of the investigated microRNAs were identified using MirTargetLink, Tarbase v9.0, and LinkedOmics services. Gene Set Enrichment Analysis was performed using Metascape. The relations between the level of microRNA expression and clinical SCC features (according to TCGA data, CESC sample) were searched using USCS Xena service. RESULTS: NGS-sequencing of paired HPV16-positive specimens of tumor tissue and normal cervical tissue resulted in the identification of 42 differentially expressed microRNAs. Specifically, the levels of 22 microRNAs in the tumor tissue were higher than in the apparently normal adjacent epithelium, while 20 microRNAs demonstrated lower levels in the tumor specimens. Analysis of the potential targets of significant microRNAs revealed multiple functional gene categories, potentially involved in carcinogenesis as well as an association with clinical features. We showed that increased expression levels of microRNA-20b in the tumor tissue correlated with the risk of distant metastases, whereas the lower levels of microRNA-218-1 and microRNA -218-2 were associated with unfavorable prognosis of disease. With regard to microRNA-363, -615, and -769, their increase in cervical cancer was described for the first time, and the potential targets and signaling pathways associated with THEIR EXPRESSION LEVELS WERE IDENTIFIED. CONCLUSION: The search for differentially expressed microRNAs in cervical cancer has revealed a spectrum of microRNAs with potentially important role in the process of malignant transformation and persistence of tumor phenotype. In addition to microRNAs demonstrating functional characteristics described in the world literature, we found microRNAs that play an unknown role in cervical cancer. In this relation, the potentially relevant targets were identified that could be helpful in understanding the mechanisms of carcinogenesis. The data obtained may form the basis for the development of new approaches to the diagnosis and therapy of SCC.
- Open Access
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 183-194
Viral microRNA in HPV16-associated cervical cancer: expression, diagnostic potential, and biological functions
BACKGROUND: Cervical cancer (CC) is the fourth most common cancer among women worldwide in terms of incidence and mortality. High-risk human papillomaviruses (HPVs) are etiologic factor of CC in more than 90% of cases, with type 16 HPV (HPV16) revealed in 50% of cancers. Dysregulation of expression of viral oncogenes E6 and E7 is the main cause of malignant transformation in infected cervical epithelial cells. The mechanisms of impaired expression of these genes are still underexplored. The dysfunction of viral microRNAs may be among the underlying factors. AIM: To analyze the expression of HPV16-associated microRNA-H1 and microRNA-H2 in cervical cancer specimens, evaluate the correlation of their expression to viral load and overall patient survival, and analyze in silico their potential viral and cellular targets. MATERIALS AND METHODS: The expression of HPV16 microRNA-H1 and HPV16 microRNA-H2 was evaluated in the real-time polymerase chain reaction. With this purpose, small RNAs were isolated from 36 specimens of HPV16-positive squamous cell carcinomas of the cervix. Further, the viral load was assessed after calculating the value of HPV16 DNA copies per cell. The association between microRNA expression and the viral load was evaluated using the nonparametric Spearman’s correlation coefficient. Kaplan-Meier curves were plotted to analyze the dependence of 5-year overall survival on the level of viral microRNA expression. The miRanda algorithm and online services mirDB, MR-microT and TargetScan Custom 5.2 were used for in silico search of theoretical microRNA targets. RESULTS: MicroRNA-H1 expression was revealed in 33 of 38 specimens (86.8%), microRNA-H2 was detected in 37 of 38 specimens (97.4%) of HPV16-positive cervical cancer. There was a positive correlation between both microRNA-H1 (r=0.36, p=0.042) and microRNA-H2 (r=0.51, p=0.001) expression and HPV16 viral load. Higher level of expression of viral microRNA-H1 and microRNA-H2 tended to correlate with better overall patient survival. The theoretical microRNA-H1 (E7, E2, E5, L2 and URR) and microRNA-H2 (E1, E2, E5, L2, L1, URR) targets in the HPV16 genome were identified in silico, as well as theoretical cellular targets indicating possible regulation of cellular signaling pathways by means of viral microRNAs, both controlling normal viral cycle and promoting tumor transformation. CONCLUSION: The results of this study demonstrate promising further investigation of the functions of viral microRNAs in relation with the infectious process and virus-induced malignant transformation, and their potential importance in the diagnosis of HPV16-associated cancers.
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 183-194
Open AccessViral microRNA in HPV16-associated cervical cancer: expression, diagnostic potential, and biological functions
BACKGROUND: Cervical cancer (CC) is the fourth most common cancer among women worldwide in terms of incidence and mortality. High-risk human papillomaviruses (HPVs) are etiologic factor of CC in more than 90% of cases, with type 16 HPV (HPV16) revealed in 50% of cancers. Dysregulation of expression of viral oncogenes E6 and E7 is the main cause of malignant transformation in infected cervical epithelial cells. The mechanisms of impaired expression of these genes are still underexplored. The dysfunction of viral microRNAs may be among the underlying factors. AIM: To analyze the expression of HPV16-associated microRNA-H1 and microRNA-H2 in cervical cancer specimens, evaluate the correlation of their expression to viral load and overall patient survival, and analyze in silico their potential viral and cellular targets. MATERIALS AND METHODS: The expression of HPV16 microRNA-H1 and HPV16 microRNA-H2 was evaluated in the real-time polymerase chain reaction. With this purpose, small RNAs were isolated from 36 specimens of HPV16-positive squamous cell carcinomas of the cervix. Further, the viral load was assessed after calculating the value of HPV16 DNA copies per cell. The association between microRNA expression and the viral load was evaluated using the nonparametric Spearman’s correlation coefficient. Kaplan-Meier curves were plotted to analyze the dependence of 5-year overall survival on the level of viral microRNA expression. The miRanda algorithm and online services mirDB, MR-microT and TargetScan Custom 5.2 were used for in silico search of theoretical microRNA targets. RESULTS: MicroRNA-H1 expression was revealed in 33 of 38 specimens (86.8%), microRNA-H2 was detected in 37 of 38 specimens (97.4%) of HPV16-positive cervical cancer. There was a positive correlation between both microRNA-H1 (r=0.36, p=0.042) and microRNA-H2 (r=0.51, p=0.001) expression and HPV16 viral load. Higher level of expression of viral microRNA-H1 and microRNA-H2 tended to correlate with better overall patient survival. The theoretical microRNA-H1 (E7, E2, E5, L2 and URR) and microRNA-H2 (E1, E2, E5, L2, L1, URR) targets in the HPV16 genome were identified in silico, as well as theoretical cellular targets indicating possible regulation of cellular signaling pathways by means of viral microRNAs, both controlling normal viral cycle and promoting tumor transformation. CONCLUSION: The results of this study demonstrate promising further investigation of the functions of viral microRNAs in relation with the infectious process and virus-induced malignant transformation, and their potential importance in the diagnosis of HPV16-associated cancers.
- Open Access
- 15 September 2024
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 11 (3) , 56-67
Diagnostic potential of miRNA-135A1 in human papillomavirus associated cervical lesions
Introduction. Human papillomavirus (HPV) infection with high-risk HPVs is an etiological factor in the development of cervical cancer, with HPV type 16 (HPV16) being the most common. The mechanisms leading to disruption of viral oncogene expression and initiation of epithelial cell transformation are poorly understood. Epigenetic regulatory factors, including cellular miRNAs, may play an important role in HPV-induced carcinogenesis, and aberrantly expressed miRNAs may be promising markers for the diagnosis of HPV-associated lesions.Aim. To search for miRNAs involved in the pathogenesis of HPV16-associated cervical cancer and to evaluate their diagnostic potential for the detection of cervical cancer and precancerous lesions.Materials and methods. MiRNA expression in clinical samples was assessed by both next generation sequencing and quantitative stem-loop polymerase chain reaction (sl-qPCR). Plasma miRNAs from patients with precancerous and cancerous lesions and healthy donors were analyzed using sl-qPCR. Loss of heterozygosity in cervical cancer samples was assessed by copy number ratio of MIR135A1 and ACTB genes. A total of 67 patients with cervical cancer, 21 with precancerous cervical lesions and 24 healthy donors were included in the study. The effect of DNA methylation on miRNA-135A1 expression was evaluated after treatment with a demethylating agent of the cervical HPV16-positive SiHa cell line. Changes in the expression of the HPV16 E6 oncogene were analyzed after transfection with synthetic analogues of the mature forms of miRNA-135А1 (miRNA-135a-3p and miRNA-135a-5p).Results. A significant decrease in the expression of miRNA-135A1 and miRNA-135A2 was detected in tumor tissue samples from HPV16-positive cervical cancer, which was confirmed by sl-qPCR in an independent panel of tumor samples. A decrease in miRNA-135A1 expression was shown to result from both loss of heterozygosity of the gene and aberrant DNA methylation. Transfection of mature forms of miRNA-135A1 into SiHa cells resulted in decreased expression of the E6 oncogene of HPV16. Blood plasma samples from patients with cervical cancer and precancerous lesions showed lower levels of miRNA-135a-3p than healthy donors, and ROC analysis indicated its high diagnostic potential.Conclusion. Levels of miRNA-135A1 are significantly reduced in cervical lesions, both in tumor tissue and plasma, and the ability of this miRNA to suppress the expression of the HPV16 E6 oncogene suggests its oncosuppressive properties. Thus, miRNA-135A1 can be used as a promising new marker for the diagnosis of HPV-associated lesions.
- 15 September 2024
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 11 (3) , 56-67
Open AccessDiagnostic potential of miRNA-135A1 in human papillomavirus associated cervical lesions
Introduction. Human papillomavirus (HPV) infection with high-risk HPVs is an etiological factor in the development of cervical cancer, with HPV type 16 (HPV16) being the most common. The mechanisms leading to disruption of viral oncogene expression and initiation of epithelial cell transformation are poorly understood. Epigenetic regulatory factors, including cellular miRNAs, may play an important role in HPV-induced carcinogenesis, and aberrantly expressed miRNAs may be promising markers for the diagnosis of HPV-associated lesions.Aim. To search for miRNAs involved in the pathogenesis of HPV16-associated cervical cancer and to evaluate their diagnostic potential for the detection of cervical cancer and precancerous lesions.Materials and methods. MiRNA expression in clinical samples was assessed by both next generation sequencing and quantitative stem-loop polymerase chain reaction (sl-qPCR). Plasma miRNAs from patients with precancerous and cancerous lesions and healthy donors were analyzed using sl-qPCR. Loss of heterozygosity in cervical cancer samples was assessed by copy number ratio of MIR135A1 and ACTB genes. A total of 67 patients with cervical cancer, 21 with precancerous cervical lesions and 24 healthy donors were included in the study. The effect of DNA methylation on miRNA-135A1 expression was evaluated after treatment with a demethylating agent of the cervical HPV16-positive SiHa cell line. Changes in the expression of the HPV16 E6 oncogene were analyzed after transfection with synthetic analogues of the mature forms of miRNA-135А1 (miRNA-135a-3p and miRNA-135a-5p).Results. A significant decrease in the expression of miRNA-135A1 and miRNA-135A2 was detected in tumor tissue samples from HPV16-positive cervical cancer, which was confirmed by sl-qPCR in an independent panel of tumor samples. A decrease in miRNA-135A1 expression was shown to result from both loss of heterozygosity of the gene and aberrant DNA methylation. Transfection of mature forms of miRNA-135A1 into SiHa cells resulted in decreased expression of the E6 oncogene of HPV16. Blood plasma samples from patients with cervical cancer and precancerous lesions showed lower levels of miRNA-135a-3p than healthy donors, and ROC analysis indicated its high diagnostic potential.Conclusion. Levels of miRNA-135A1 are significantly reduced in cervical lesions, both in tumor tissue and plasma, and the ability of this miRNA to suppress the expression of the HPV16 E6 oncogene suggests its oncosuppressive properties. Thus, miRNA-135A1 can be used as a promising new marker for the diagnosis of HPV-associated lesions.
- Open Access
- 14 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 149-156
The effect of DNA methyltransferase 3A suppression in progression of the resistance phenotype in breast cancer cells
Introduction. Rearrangement of molecular pathways and activation of bypass signaling determine the progression of tumor cell resistance to various drugs. Study of the common features of resistant formation mechanisms is essential for breast and other cancer beneficial treatments.Materials and methods. The present work was performed on estrogen receptor α ERα-positive (ERα – estrogen receptor α) McF-7 breast cancer cells, established sublines resistant to the mTOR inhibitor rapamycin or antiestrogen tamoxifen, and ERα-negative MDA-MB-231 breast cancer cells. Methods used include MTT test, transient transfection, immunoblotting, real-time polymerase chain reaction and methylation analysis by bisulfite pyrosequencing.Results. We have shown that the resistance of breast cancer cells to targeted and hormonal drugs is associated with the suppression of DNA methyltransferase 3A (DNMT3A) and respective changes in DNA methylation; DNMT3A knockdown results in the partial resistance to both drugs demonstrating the pivotal role of DNMT3A suppression in the progression of cell resistance.Conclusion. Totally, the results obtained highlight the possible mechanism of tumor cell resistance to targeting/hormonal drugs based on the deregulation of DNMTs expression and demonstrate direct connection between DNMT3A suppression and resistance progression.
- 14 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 149-156
Open AccessThe effect of DNA methyltransferase 3A suppression in progression of the resistance phenotype in breast cancer cells
Introduction. Rearrangement of molecular pathways and activation of bypass signaling determine the progression of tumor cell resistance to various drugs. Study of the common features of resistant formation mechanisms is essential for breast and other cancer beneficial treatments.Materials and methods. The present work was performed on estrogen receptor α ERα-positive (ERα – estrogen receptor α) McF-7 breast cancer cells, established sublines resistant to the mTOR inhibitor rapamycin or antiestrogen tamoxifen, and ERα-negative MDA-MB-231 breast cancer cells. Methods used include MTT test, transient transfection, immunoblotting, real-time polymerase chain reaction and methylation analysis by bisulfite pyrosequencing.Results. We have shown that the resistance of breast cancer cells to targeted and hormonal drugs is associated with the suppression of DNA methyltransferase 3A (DNMT3A) and respective changes in DNA methylation; DNMT3A knockdown results in the partial resistance to both drugs demonstrating the pivotal role of DNMT3A suppression in the progression of cell resistance.Conclusion. Totally, the results obtained highlight the possible mechanism of tumor cell resistance to targeting/hormonal drugs based on the deregulation of DNMTs expression and demonstrate direct connection between DNMT3A suppression and resistance progression.